The study to evaluate the efficacy and resistance for EGFR-TKIs treatment in lung cancer patients.

The study to evaluate the efficacy and resistance for EGFR-TKIs treatment in lung cancer patients. - The study to evaluate the efficacy and resistance for EGFR-TKIs treatment in lung cancer patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002193

Enrollment

Registered

2009-07-14

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

EGFR-TKIs, analysis of genomic profiles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lung cancer patients with EGFR-TKIs. All patients give written informed consent.

Exclusion criteria

Exclusion criteria: except for the above-mentioned

Design outcomes

Primary

Measure	Time frame
corrlation of genomic profile and efficacy and resistance	—

Secondary

Measure	Time frame
adverse ivent, survival, patinets characteristics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026